S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
Log in

NASDAQ:ATRC - AtriCure Stock Price, Forecast & News

$43.16
-0.68 (-1.55 %)
(As of 02/18/2020 04:00 PM ET)
Today's Range
$43.11
Now: $43.16
$44.51
50-Day Range
$32.37
MA: $37.54
$43.84
52-Week Range
$22.57
Now: $43.16
$44.51
Volume562,802 shs
Average Volume371,072 shs
Market Capitalization$1.71 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.29
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ATRC
CUSIP04963C20
Phone513-755-4100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$201.63 million
Book Value$6.47 per share

Profitability

Net Income$-21,140,000.00

Miscellaneous

Employees620
Market Cap$1.71 billion
Next Earnings Date2/18/2020 (Confirmed)
OptionableOptionable

Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.


AtriCure (NASDAQ:ATRC) Frequently Asked Questions

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

How were AtriCure's earnings last quarter?

AtriCure Inc. (NASDAQ:ATRC) announced its quarterly earnings results on Wednesday, October, 30th. The medical device company reported ($0.25) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.28) by $0.03. The medical device company earned $56.60 million during the quarter, compared to analyst estimates of $55.12 million. AtriCure had a negative return on equity of 13.59% and a negative net margin of 10.13%. AtriCure's revenue for the quarter was up 13.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.24) EPS. View AtriCure's Earnings History.

When is AtriCure's next earnings date?

AtriCure is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for AtriCure.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, February, 18th. The company provided earnings per share guidance of -1.24--1.14 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $-1.09. The company issued revenue guidance of $254-261 million, compared to the consensus revenue estimate of $258.71 million.

What price target have analysts set for ATRC?

6 brokers have issued 12-month price objectives for AtriCure's shares. Their forecasts range from $30.00 to $48.00. On average, they anticipate AtriCure's stock price to reach $39.50 in the next twelve months. This suggests that the stock has a possible downside of 8.5%. View Analyst Price Targets for AtriCure.

What is the consensus analysts' recommendation for AtriCure?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AtriCure.

Has AtriCure been receiving favorable news coverage?

News headlines about ATRC stock have trended extremely negative on Tuesday, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. AtriCure earned a coverage optimism score of -4.0 on InfoTrie's scale. They also gave news headlines about the medical device company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for AtriCure.

Are investors shorting AtriCure?

AtriCure saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 873,400 shares, an increase of 11.7% from the January 15th total of 781,900 shares. Based on an average daily volume of 234,200 shares, the short-interest ratio is presently 3.7 days. Currently, 2.3% of the company's stock are sold short. View AtriCure's Current Options Chain.

Who are some of AtriCure's key competitors?

What other stocks do shareholders of AtriCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Amgen (AMGN), Gilead Sciences (GILD), Enterprise Products Partners (EPD), Neurocrine Biosciences (NBIX), Allergan (AGN), bluebird bio (BLUE), Cellectis (CLLS), Intel (INTC) and Abbott Laboratories (ABT).

Who are AtriCure's key executives?

AtriCure's management team includes the folowing people:
  • Mr. Michael H. Carrel, CEO, Pres & Director (Age 48)
  • Mr. M. Andrew Wade CPA, Sr. VP & CFO (Age 44)
  • Mr. Douglas J. Seith, Chief Operating Officer (Age 53)
  • Mr. Salvatore Privitera, Chief Technology Officer (Age 52)
  • Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 41)

Who are AtriCure's major shareholders?

AtriCure's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.99%), Champlain Investment Partners LLC (3.16%), GW&K Investment Management LLC (2.96%), State Street Corp (2.49%), Tamarack Advisers LP (2.17%) and Peregrine Capital Management LLC (1.93%). Company insiders that own AtriCure stock include Douglas J Seith, Elizabeth D Krell, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel and Regina E Groves. View Institutional Ownership Trends for AtriCure.

Which major investors are selling AtriCure stock?

ATRC stock was sold by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, Prudential Financial Inc., Man Group plc, SG Americas Securities LLC, Martingale Asset Management L P, Peregrine Capital Management LLC, Bessemer Group Inc. and Oxford Asset Management LLP. Company insiders that have sold AtriCure company stock in the last year include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar and Michael H Carrel. View Insider Buying and Selling for AtriCure.

Which major investors are buying AtriCure stock?

ATRC stock was acquired by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, Bridger Management LLC, GW&K Investment Management LLC, Point72 Asset Management L.P., Renaissance Technologies LLC, Landscape Capital Management L.L.C., BNP PARIBAS ASSET MANAGEMENT Holding S.A. and Sectoral Asset Management Inc. View Insider Buying and Selling for AtriCure.

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $43.16.

How big of a company is AtriCure?

AtriCure has a market capitalization of $1.71 billion and generates $201.63 million in revenue each year. The medical device company earns $-21,140,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. AtriCure employs 620 workers across the globe.View Additional Information About AtriCure.

What is AtriCure's official website?

The official website for AtriCure is http://www.atricure.com/.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.


MarketBeat Community Rating for AtriCure (NASDAQ ATRC)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  451 (Vote Outperform)
Underperform Votes:  334 (Vote Underperform)
Total Votes:  785
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe ATRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel